Research ExplorerPublicationsThe novel nomogram of Gleason sum upgrade: possible applicat...

The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.

Standard

The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy. / Budäus, Lars; Graefen, Markus; Salomon, Georg; Isbarn, Hendrik; Lughezzani, Giovanni; Sun, Maxine; Chun, Felix; Schlomm, Thorsten; Steuber, Thomas; Haese, Alexander; Köllermann, Jens; Sauter, Guido; Fisch, Margit; Heinzer, Hans; Huland, Hartwig; Karakiewicz, Pierre I.

In: INT J UROL, Vol. 17, No. 10, 10, 2010, p. 862-868.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Budäus, L, Graefen, M, Salomon, G, Isbarn, H, Lughezzani, G, Sun, M, Chun, F, Schlomm, T, Steuber, T, Haese, A, Köllermann, J, Sauter, G, Fisch, M, Heinzer, H, Huland, H & Karakiewicz, PI 2010, 'The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.', INT J UROL, vol. 17, no. 10, 10, pp. 862-868. <http://www.ncbi.nlm.nih.gov/pubmed/20812920?dopt=Citation>

APA

Budäus, L., Graefen, M., Salomon, G., Isbarn, H., Lughezzani, G., Sun, M., Chun, F., Schlomm, T., Steuber, T., Haese, A., Köllermann, J., Sauter, G., Fisch, M., Heinzer, H., Huland, H., & Karakiewicz, P. I. (2010). The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy. INT J UROL, 17(10), 862-868. [10]. http://www.ncbi.nlm.nih.gov/pubmed/20812920?dopt=Citation

Vancouver

Budäus L, Graefen M, Salomon G, Isbarn H, Lughezzani G, Sun M et al. The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy. INT J UROL. 2010;17(10):862-868. 10.

Bibtex

@article{e00e6afc8a134778b0c360324f7cb713,
title = "The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.",
abstract = "To examine the rate of Gleason sum upgrading (GSU) from a sum of 6 to a Gleason sum of 7 in patients undergoing radical prostatectomy (RP), who fulfilled the recommendations for low dose rate brachytherapy (Gleason sum 6, prostate-specific antigen 10 ng/mL, clinical stage T2a and prostate volume 50 mL), and to test the performance of an existing nomogram for prediction of GSU in this specific cohort of patients.",
author = "Lars Bud{\"a}us and Markus Graefen and Georg Salomon and Hendrik Isbarn and Giovanni Lughezzani and Maxine Sun and Felix Chun and Thorsten Schlomm and Thomas Steuber and Alexander Haese and Jens K{\"o}llermann and Guido Sauter and Margit Fisch and Hans Heinzer and Hartwig Huland and Karakiewicz, {Pierre I}",
year = "2010",
language = "Deutsch",
volume = "17",
pages = "862--868",
journal = "INT J UROL",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.

AU - Budäus, Lars

AU - Graefen, Markus

AU - Salomon, Georg

AU - Isbarn, Hendrik

AU - Lughezzani, Giovanni

AU - Sun, Maxine

AU - Chun, Felix

AU - Schlomm, Thorsten

AU - Steuber, Thomas

AU - Haese, Alexander

AU - Köllermann, Jens

AU - Sauter, Guido

AU - Fisch, Margit

AU - Heinzer, Hans

AU - Huland, Hartwig

AU - Karakiewicz, Pierre I

PY - 2010

Y1 - 2010

N2 - To examine the rate of Gleason sum upgrading (GSU) from a sum of 6 to a Gleason sum of 7 in patients undergoing radical prostatectomy (RP), who fulfilled the recommendations for low dose rate brachytherapy (Gleason sum 6, prostate-specific antigen 10 ng/mL, clinical stage T2a and prostate volume 50 mL), and to test the performance of an existing nomogram for prediction of GSU in this specific cohort of patients.

AB - To examine the rate of Gleason sum upgrading (GSU) from a sum of 6 to a Gleason sum of 7 in patients undergoing radical prostatectomy (RP), who fulfilled the recommendations for low dose rate brachytherapy (Gleason sum 6, prostate-specific antigen 10 ng/mL, clinical stage T2a and prostate volume 50 mL), and to test the performance of an existing nomogram for prediction of GSU in this specific cohort of patients.

M3 - SCORING: Zeitschriftenaufsatz

VL - 17

SP - 862

EP - 868

JO - INT J UROL

JF - INT J UROL

SN - 0919-8172

IS - 10

M1 - 10

ER -